This reflects the fact that potent and highly active (at least in preclinical models) NAMPT inhibitors, such as FK866 and CHS828, were among the first NAD-lowering agents to be reported [15,16,17] and the observation that NAMPT is commonly overexpressed in a variety of human cancers [17,18]. Here, NAMPT is linked to cancer.